4 September 2024 - Celltrion said its Stelara (ustekinumab) biosimilar, Steqeyma, received marketing authorisation from the UK MHRA.

Steqeyma is set to treat various inflammatory diseases including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Read Korea Biomedical Review article